3 results about "Allergy medications" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to application of a compound in preparation of an anti-allergic medicine. The degranulation inhibition effect is verified through a mast cell in-vitro culture model, the overall anti-allergic activity is verified by combining an animal allergy model, and a series of experiments prove that the compound A33 can inhibit I-type anaphylaxis (such as ear and subcutaneous anaphylaxis) mediated by an IgE antibody. Different from a traditional anti-allergic drug (such as an antihistamine drug), the compound A33 is used for preventing release of media such as TNF-alpha and IL-6 from the source in an anaphylactic reaction starting link that the compound A33 directly inhibits mast cell degranulation in allusion to downstream blocking of an allergic medium, so that the compound A33 is introduced into the field of anti-allergic product research; a new candidate strategy with a clear targeting mechanism and an experimental basis is provided for prevention and / or treatment of allergic diseases, and the application value in anti-allergic drugs, cosmetics or daily chemical products is wide.

This invention discloses a fusion peptide with synergistic anti-allergic effects, an anti-LTB4 monoclonal antibody, and an anti-allergic drug composition thereof. The fusion peptide is composed of peptide A, which inhibits histamine release, and peptide B, which blocks mast cell activation signals, covalently linked by a linker peptide, which can synergistically inhibit mast cell activation. The anti-LTB4 monoclonal antibody can specifically bind to LTB4, blocking its mediated inflammatory response. Combining the fusion peptide, the anti-LTB4 monoclonal antibody, and myricetin, which has antioxidant activity, forms a multi-target drug composition that can synergistically inhibit allergic reactions from multiple aspects, such as inhibiting mast cell degranulation, blocking the action of inflammatory mediators, and clearing oxidative stress products. In vitro cell experiments and OVA-induced allergic asthma mouse models have demonstrated that the anti-allergic effect of this composition is significantly better than that of a single component, and it has no obvious toxicity, providing a new candidate drug for the efficient treatment of allergic diseases.

The invention discloses a mast cell targeted hydrogen sulfide controlled release nano stabilizer as well as a preparation method and application thereof, and belongs to the technical field of nano biological materials and drug delivery. The nano stabilizer (SMSNs (at) SC (at) HA) takes tetrasulfide bond bridged mesoporous organosilicon nanoparticles as a skeleton, an anti-allergic drug sodium cromoglycate (SC) is loaded in mesoporous channels of the mesoporous organosilicon nanoparticles, and hyaluronic acid (HA) is modified on the surfaces of the nanoparticles through covalent bonds. Wherein the tetrasulfide bond can be broken in a reducing environment in cells, so that not only can the controllable and continuous release of hydrogen sulfide gas be realized, but also the degradation of the skeleton structure of the nano stabilizer can be induced, and the release behavior of the loaded drug SC can be cooperatively regulated and controlled; hA realizes targeted recognition of mast cells in a receptor mediation mode, and non-specific leakage of the medicine in a body fluid environment is effectively reduced. The preparation method of the nano stabilizer provided by the invention is mild in process condition, good in repeatability and convenient for industrial amplification. In addition, the nano stabilizer is further applied to a passive skin anaphylaxis model, and a new strategy is provided for preparing the long-term and safe nano stabilizer with a targeting function.